New hope for muscle disease: drug trial launches
NCT ID NCT07355257
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called telitacicept in 30 adults with inflammatory myopathy, a condition where the immune system attacks muscles, causing weakness. The goal is to see if the drug is safe and can control the disease. Participants must have not responded well to standard treatments like steroids.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATORY MYOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at Hard-to-Treat muscle disease
- Engineered immune cells take aim at Hard-to-Treat autoimmune diseases
- Video game rehab boosts muscle power in rare muscle disease
- New cell therapy hopes to tame tough autoimmune diseases
- Engineered immune cells aim to tame stubborn autoimmune diseases
- Experimental cell therapy takes on lupus and other autoimmune diseases